Drug Trial Radar · NCT02520284
Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Apr 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
165
Actual
Start
Sep 2015
Primary completion
Sep 2016
Study completion Nov 2016
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 11, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are as follows: 1) To evaluate the efficacy of andecaliximab to induce endoscopy, rectal bleeding, and stool frequency (EBS) clinical remission at Week 8 (Cohort 1); 2) To evaluate the efficacy of andecaliximab to maintain EBS clinical remission at Week 52 (Cohort 2); and 3) To evaluate the safety and tolerability of andecaliximab. The study will consist of 3 parts: Induction Phase (Cohort 1), Maintenance Phase (Cohort 2), and an optional Extended Treatment Phase.
Conditions
- Ulcerative Colitis
Interventions
AndecaliximabBiological
Andecaliximab 150 mg administered via SC injection
PlaceboBiological
Placebo matched to andecaliximab administered via SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8Time frame: Week 8
Locations
87 sites in 23 countries. Site status is shown where the registry gives one.
Site not named
Dothan, Alabama
Site not named
Wheat Ridge, Colorado
Site not named
Lauderdale Lakes, Florida
Site not named
Miramar, Florida
Site not named
Winter Park, Florida
Site not named
Zephyrhills, Florida
Site not named
Chicago, Illinois
Site not named
Topeka, Kansas
Site not named
Louisville, Kentucky
Site not named
Monroe, Louisiana
Site not named
Ann Arbor, Michigan
Site not named
Plymouth, Minnesota
Site not named
St Louis, Missouri
Site not named
Egg Harbor, New Jersey
Site not named
New York, New York
Site not named
Chapel Hill, North Carolina
Site not named
Charlotte, North Carolina
Site not named
Mentor, Ohio
Site not named
Rochester, Ohio
Site not named
Germantown, Tennessee
Site not named
Hermitage, Tennessee
Site not named
Arlington, Texas
Site not named
Baytown, Texas
Site not named
Houston, Texas
Site not named
Irving, Texas
Site not named
San Antonio, Texas
Site not named
Southlake, Texas
Site not named
Charlottesville, Virginia
Site not named
Chesapeake, Virginia
Site not named
Norfolk, Virginia
Site not named
Richmond, Virginia
Site not named
Seattle, Washington
Site not named
Wauwatosa, Wisconsin
Site not named
Footscray, Australia
Site not named
Herston, Australia
Site not named
Malvern, Australia
Site not named
Melbourne, Australia
Site not named
Ghent, Belgium
Site not named
Leuven, Belgium
Site not named
Mouscron, Belgium
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.